BICO invites to a presentation, later today, December 16, to inform about the acquisition of Biosero during two different occasions to be able to, from a time zone perspective fit both the European and the US investor base. Biosero is a San Diego based company, with 75 employees globally and founded in 2003. The company offers software solutions, under the umbrella of Green Button Go and services which enable seamless laboratory automation for connected and smart workflows.

  • The presentation will focus on the rationale of the acquisition, presentation of Biosero and synergies going forward. The presentation will end with a Q&A.
  • Agenda, speakers, and the presentation will be the same during both sessions.
  • The presentation will be held in English and will be available at 8.30am CET on bico.com/investors.
     

Date: Thursday December 16, 2021

Europe: 10am CET
For audio: +46 8 502 439 36 Conference-ID: 387 258 521#
For video: Video link to the presentation

USA: 3pm CET/9am EST
For audio: +46 8 502 439 36 Conference-ID: 834 767 152#
For video: Video link to the presentation

Speakers: Erik Gatenholm, CEO BICO, Gusten Danielsson, CFO BICO, Dr. Jonas Schöndube, SVP and Business Area Director Biosciences BICO and Tom Gilman, CEO Biosero.  

Please note for the Q&A session you have two options: a) if you participate via audio, you can ask your questions directly to the speakers b) if you participate via video, you can only ask questions via the chat function.

For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70830 0890
Email: il@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on December 16, 2021, at 08:00 (CET).

About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.  

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com